Loading...
•
Dec 31, 2025
Incyte Q4 2025 Earnings Report
Incyte reported strong financial results for the fourth quarter and full year ended December 31, 2025, driven by significant increases in total revenue and net product revenue, exceeding full-year guidance.
Key Takeaways
Incyte delivered exceptional core business growth and pipeline progress in Q4 2025, with total revenue increasing by 28% year-over-year to $1.51 billion and net product revenue rising by 20% to $1.22 billion, surpassing full-year guidance. The company also reported a significant increase in GAAP net income to $299.28 million and GAAP basic EPS to $1.52.
Total revenue for Q4 2025 increased by 28% year-over-year to $1.51 billion, primarily due to higher net product revenue and milestone and contract revenue.
Total net product revenue for Q4 2025 grew by 20% year-over-year to $1.22 billion, driven by strong demand for Jakafi and Opzelura cream, and robust uptake of Niktimvo and Zynyz.
GAAP net income for Q4 2025 was $299.28 million, a substantial increase from $201.21 million in Q4 2024.
GAAP basic EPS for Q4 2025 was $1.52, up from $1.04 in Q4 2024.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Incyte provided full year 2026 total net product revenue guidance ranging from $4.77 billion to $4.94 billion, with specific guidance for Jakafi, Opzelura, and Hematology and Oncology net product revenue. The company anticipates continued investment in its pipeline and upcoming potential launches.
Positive Outlook
- Total net product revenue guidance for 2026 is $4.77 billion to $4.94 billion, indicating continued growth.
- Jakafi net product revenue guidance for 2026 is $3.22 billion to $3.27 billion, including the initial launch of Jakafi XR.
- Opzelura net product revenue guidance for 2026 is $750 million to $790 million, including anticipated ex-U.S. launch in moderate AD.
- Hematology and Oncology net product revenue guidance for 2026 is $800 million to $880 million.
- The company expects to have fourteen pivotal clinical trials underway by the end of 2025, indicating a robust pipeline.
Challenges Ahead
- Total GAAP R&D and SG&A operating expense guidance for 2026 is $3.495 billion to $3.675 billion, reflecting continued investment and costs associated with potential launches.
- Total non-GAAP R&D and SG&A operating expense guidance for 2026 is $3.205 billion to $3.375 billion.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...